{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:48:44Z","timestamp":1792586924988,"version":"4.5.0"},"reference-count":61,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: HIV-exposed uninfected (HEU) infants experience increased severe respiratory syncytial virus lower respiratory tract illness (RSV-LRTI) rates compared with HIV-unexposed infants. Maternal bivalent RSVpreF vaccination can prevent infant RSV-LRTI but data from HEU infants are lacking. Methods: This phase 3 randomized, double-blinded trial assessed RSVpreF safety and immunogenicity in pregnant participants from South Africa living with HIV and their infants. Maternal participants with stable HIV disease taking antiretroviral therapy received RSVpreF or placebo (24\u201336 weeks\u2019 gestation). Primary safety endpoints included reactogenicity through 7 days after vaccination (maternal participants), adverse events (AEs) through 1 month after vaccination (maternal participants) or birth (infants), and serious AEs (SAEs) throughout the study (maternal participants) or through 6 months after birth (infants). Immune responses were evaluated by 50% RSV-A and RSV-B neutralizing titers prevaccination and at delivery (maternal participants) or birth (infants). Results: Overall, 343 maternal participants received RSVpreF (n = 172) or placebo (n = 171). Most reactogenicity events were mild\/moderate. AEs and SAEs were generally reported at similar frequencies in maternal RSVpreF and placebo groups including percentages of hypertensive disorders of pregnancy. There were no safety concerns in infants; percentages of reported AEs and SAEs were generally similar between RSVpreF and placebo groups and no difference in preterm birth. RSVpreF elicited high maternal neutralizing RSV-A and RSV-B immune responses, with efficient RSV antibody transplacental transfer to infants demonstrated by levels greater than the placebo group at birth (geometric mean ratios (GMRs) of RSVpreF to placebo were 7.8 for RSV-A and 6.8 for RSV-B) and by comparison with a cohort of HIV-unexposed infants from the pivotal phase 3 efficacy trial (GMRs of HEU to HIV-unexposed infants were 0.86 for RSV-A and 0.72 for RSV-B). Conclusions: These results support maternal RSVpreF vaccination among those living with stable HIV for preventing RSV-LRTI in HEU infants. (NCT06325657).<\/jats:p>","DOI":"10.3390\/vaccines13121218","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T08:49:22Z","timestamp":1764665362000},"page":"1218","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety, Tolerability, and Immunogenicity of RSVpreF Vaccine in Pregnant Individuals Living with HIV"],"prefix":"10.3390","volume":"13","author":[{"given":"Landon","family":"Myer","sequence":"first","affiliation":[{"name":"Division of Epidemiology and Biostatistics, School of Public Health, University of Cape Town, Cape Town 7925, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Wasserman","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc., Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiqa","family":"Tabasum","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Ltd., Buckinghamshire, SL7 1YL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Shittu","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Ltd., Buckinghamshire, SL7 1YL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Liu","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc., Collegeville, PA 19426, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Jose","sequence":"additional","affiliation":[{"name":"South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand, Johannesburg 1864, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9236-3110","authenticated-orcid":false,"given":"Elizea","family":"Horne","sequence":"additional","affiliation":[{"name":"Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2001, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Moraba","sequence":"additional","affiliation":[{"name":"Setshaba Research Centre, Tshwane City 0152, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agatha","family":"Wilhase","sequence":"additional","affiliation":[{"name":"REIMED (Pty) Ltd., Johannesburg 1459, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9046-759X","authenticated-orcid":false,"given":"Heather J.","family":"Zar","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Child Health, Red Cross War Memorial Children\u2019s Hospital, SA-MRC Unit on Child & Adolescent Health, University of Cape Town, Cape Town 8001, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazreen","family":"Hussen","sequence":"additional","affiliation":[{"name":"Worthwhile Clinical Trials, Benoni 1500, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mokgadi S.","family":"Mogashoa","sequence":"additional","affiliation":[{"name":"Botho Ke Bontle Healthcare, Pretoria 0184, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mookho","family":"Malahleha","sequence":"additional","affiliation":[{"name":"Synergy Biomed Research Institute, East London 5201, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7629-0636","authenticated-orcid":false,"given":"Shabir A.","family":"Madhi","sequence":"additional","affiliation":[{"name":"South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2195, South Africa"},{"name":"Wits Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2195, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uzma N.","family":"Sarwar","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc., Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasra","family":"Snaggs","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc., Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4397-2606","authenticated-orcid":false,"given":"Rahsan","family":"Erdem","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc., Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Radley","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc., Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena V.","family":"Kalinina","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc., Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Pahud","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc., Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Maddalena Lino","sequence":"additional","affiliation":[{"name":"Worldwide Safety, Pfizer Srl, 20152 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olympia Evdoxia","family":"Anastasiou","sequence":"additional","affiliation":[{"name":"Worldwide Safety, Pfizer Hellas SA, 55535 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3389-8414","authenticated-orcid":false,"given":"Kena A.","family":"Swanson","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc., Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliesa S.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc., Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Gurtman","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc., Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iona","family":"Munjal","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc., Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2025, July 29). The Global Health Observatory. Data on the HIV Response. Available online: https:\/\/www.who.int\/data\/gho\/data\/themes\/hiv-aids\/data-on-the-hiv-aids-response."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.21106\/ijma.404","article-title":"Perinatal HIV Transmission Prevention: Challenges among Women Living with HIV in sub-Saharan Africa","volume":"9","author":"Ruiz","year":"2020","journal-title":"Int. J. Matern. Child Health AIDS"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/QAD.0000000000002487","article-title":"Incident HIV among pregnant and breast-feeding women in sub-Saharan Africa: A systematic review and meta-analysis","volume":"34","author":"Graybill","year":"2020","journal-title":"AIDS"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Abu-Raya, B., Kollmann, T.R., Marchant, A., and MacGillivray, D.M. (2016). The immune system of HIV-exposed uninfected infants. Front. Immunol., 7.","DOI":"10.3389\/fimmu.2016.00383"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/INF.0000000000002774","article-title":"Maternal Intervention to Prevent Mother-to-Child Transmission of HIV: Moving Beyond Antiretroviral Therapy","volume":"40","author":"Mangold","year":"2021","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJM199411033311801","article-title":"Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group","volume":"331","author":"Connor","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1511691","article-title":"Benefits and risks of antiretroviral therapy for perinatal HIV prevention","volume":"375","author":"Fowler","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2214-109X(19)30448-6","article-title":"Estimates of the global population of children who are HIV-exposed and uninfected, 2000\u20132018: A modelling study","volume":"8","author":"Slogrove","year":"2020","journal-title":"Lancet. Glob. Health"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"l4479","DOI":"10.1136\/bmj.l4479","article-title":"Unmasking the vulnerabilities of uninfected children exposed to HIV","volume":"366","author":"Ramokolo","year":"2019","journal-title":"BMJ"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1016\/S1473-3099(16)00055-4","article-title":"HIV-exposed, uninfected infants: New global challenges in the era of paediatric HIV elimination","volume":"16","author":"Evans","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/cid\/ciz820","article-title":"Rates of hospitalization and infection-related hospitalization among human immunodeficiency virus (HIV)-exposed uninfected children compared to HIV-unexposed uninfected children in the United States, 2007\u20132016","volume":"71","author":"Labuda","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1093\/infdis\/jiaa490","article-title":"The impact of maternal human immunodeficiency virus infection on the burden of respiratory syncytial virus among pregnant women and their infants, Western Kenya","volume":"225","author":"Nyawanda","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/cid\/ciy1071","article-title":"Impaired transplacental transfer of respiratory syncytial virus-neutralizing antibodies in human immunodeficiency virus-infected versus -uninfected pregnant women","volume":"69","author":"Jallow","year":"2019","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/jpids\/piz056","article-title":"Placental transfer of respiratory syncytial virus antibody among HIV-exposed, uninfected infants","volume":"9","author":"Patel","year":"2020","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e20153272","DOI":"10.1542\/peds.2015-3272","article-title":"Epidemiology of acute lower respiratory tract infection in HIV-exposed uninfected infants","volume":"137","author":"Cohen","year":"2016","journal-title":"Pediatrics"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Magura, J., Nhari, S.R., and Nzimakwe, T.I. (2025). Barriers to ART adherence in sub-Saharan Africa: A scoping review toward achieving UNAIDS 95-95-95 targets. Front. Public Health, 13.","DOI":"10.3389\/fpubh.2025.1609743"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e2020047456","DOI":"10.1542\/peds.2020-047456","article-title":"Ensuring the safety of maternal immunization","volume":"147","author":"Edwards","year":"2021","journal-title":"Pediatrics"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/AOG.0000000000005816","article-title":"Efficacy, safety, and immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal respiratory syncytial virus prefusion F protein vaccine trial","volume":"145","author":"Pahud","year":"2025","journal-title":"Obstet. Gynecol."},{"key":"ref_21","unstructured":"Pfiizer Inc (2025). Abrysvo\u00ae (Respiratory Syncytial Virus Vaccine). Full Prescribing Information, Pfiizer Inc."},{"key":"ref_22","unstructured":"Electronic Medicines Compendium (2025). Package Leaflet: Information for the User. Abrysvo\u00ae Powder and Solvent for Solution for Injection, Electronic Medicines Compendium. Available online: https:\/\/www.medicines.org.uk\/emc\/files\/pil.15309.pdf."},{"key":"ref_23","unstructured":"European Medicines Agency (2025). Abrysvo (Respiratory Syncytial Virus Vaccine [Bivalent, Recombinant]), European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/abrysvo-epar-medicine-overview_en.pdf."},{"key":"ref_24","unstructured":"Therapeutic Goods Administration of Australia (2024, July 04). Australian Product Information\u2013ABRYSVO\u00ae (Recombinant Respiratory Syncytial Virus Pre-Fusion F Protein) Vaccine, Available online: https:\/\/www.tga.gov.au\/sites\/default\/files\/2024-05\/auspar-abrysvo-240502-pi.pdf."},{"key":"ref_25","unstructured":"Health Canada (2025, September 04). Respiratory Syncytial Virus (RSV) Vaccines: Canadian Immunization Guide. Available online: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/respiratory-syncytial-virus.html."},{"key":"ref_26","unstructured":"Dubai Health Authority (2025, September 04). Clinical Guidelines for Best Practice in Immunization, Available online: https:\/\/dha.gov.ae\/uploads\/102024\/Clinical%20Guideline%20for%20Best%20Practice%20in%20Immunization20241028945.pdf."},{"key":"ref_27","unstructured":"World Health Organization = Organisation Mondiale de la Sant\u00e9 (2025). Report of the 4th Joint Meeting of the WHO Global Advisory Committee on Vaccine Safety and the Advisory Committee on Safety of Medicinal Products, 12\u201314 November 2024 = Rapport de la 4e R\u00e9union Conjointe du Comit\u00e9 Consultatif Mondial de l\u2019OMS Pour la S\u00e9curit\u00e9 des Vaccins et du Comit\u00e9 Consultatif de l\u2019OMS sur la S\u00e9curit\u00e9 des Produits M\u00e9dicaux, 12\u201314 November 2024, World Health Organization = Organisation Mondiale de la Sant\u00e9."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/cid\/ciy532","article-title":"The role of human immunodeficiency virus in influenza- and respiratory syncytial virus-associated hospitalizations in South African children, 2011\u20132016","volume":"68","author":"McMorrow","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_29","unstructured":"US Food and Drug Administration (2025, April 22). Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, Available online: https:\/\/www.fda.gov\/media\/73679\/download."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/infdis\/jiab612","article-title":"A randomized phase 1\/2 study of a respiratory syncytial virus prefusion F vaccine","volume":"225","author":"Walsh","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/S1473-3099(18)30545-0","article-title":"Maternal immunisation to improve the health of HIV-exposed infants","volume":"19","author":"Bengtson","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"102448","DOI":"10.1016\/j.eclinm.2024.102448","article-title":"The safety and immunogenicity of vaccines administered to pregnant women living with HIV: A systematic review and meta-analysis","volume":"69","author":"Nakabembe","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/QAD.0000000000003758","article-title":"Maternal immunization in women living with HIV","volume":"38","author":"Dauby","year":"2024","journal-title":"AIDS"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Saso, A., and Kampmann, B. (2020). Maternal immunization: Nature meets nurture. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.01499"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s10461-024-04609-3","article-title":"PrEP Awareness and coverage: Results from the 2022 South Africa antenatal HIV sentinel survey","volume":"29","author":"Shangase","year":"2025","journal-title":"AIDS Behav."},{"key":"ref_36","unstructured":"UNAIDS (2025, September 03). Country Factsheets. South Africa. Available online: https:\/\/www.unaids.org\/en\/regionscountries\/countries\/southafrica."},{"key":"ref_37","unstructured":"Kufa-Chakezha, T., Shangase, N., Singh, B., Cutler, E., Aitken, S., Cheyip, M., Ayew, K., Lombard, C., Manda, S., and Puren, P. (2024). The 2022 Antenatal HIV Sentinel Survey-Key Findings, National Department of Health."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1097\/QAD.0000000000003039","article-title":"Increased infectious-cause hospitalization among infants who are HIV-exposed uninfected compared with HIV-unexposed","volume":"35","author":"Anderson","year":"2021","journal-title":"AIDS"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1056\/NEJMoa2106062","article-title":"Prefusion F protein-based respiratory syncytial virus immunization in pregnancy","volume":"386","author":"Center","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/AOG.0000000000005817","article-title":"Preterm birth frequency and associated outcomes from the MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal trial of the bivalent respiratory syncytial virus prefusion F protein vaccine","volume":"145","author":"Madhi","year":"2025","journal-title":"Obstet. Gynecol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/INF.0000000000003174","article-title":"Adverse pregnancy outcomes among HIV-positive women in the era of universal antiretroviral therapy remain elevated compared with HIV-negative women","volume":"40","author":"Tukei","year":"2021","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Asferie, W.N., Aytenew, T.M., Kassaw, A., Hailemeskel, H.S., Kebede, S.D., Gashaw, B.T., and Kefale, D. (2025). Effect of maternal HIV infection on birth outcomes among HIV positive women in Sub Saharan Africa: A systematic review and meta-analysis. BMC Public Health, 25.","DOI":"10.1186\/s12889-025-21497-x"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.2147\/IJWH.S382685","article-title":"Effects of HIV infection on pregnancy outcomes among women attending antenatal care in referral hospitals of the Amhara Regional State, Ethiopia: A prospective cohort study","volume":"14","author":"Worku","year":"2022","journal-title":"Int. J. Women\u2019s Health"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Deressa, A.T., Cherie, A., Belihu, T.M., and Tasisa, G.G. (2018). Factors associated with spontaneous preterm birth in Addis Ababa public hospitals, Ethiopia: Cross sectional study. BMC Pregnancy Childbirth, 18.","DOI":"10.1186\/s12884-018-1957-0"},{"key":"ref_45","first-page":"160","article-title":"Pregnancy, obstetric and neonatal outcomes in HIV positive Nigerian women","volume":"17","author":"Ezechi","year":"2013","journal-title":"Afr. J. Reprod. Health"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/S2352-3018(15)00207-6","article-title":"Perinatal outcomes associated with maternal HIV infection: A systematic review and meta-analysis","volume":"3","author":"Wedi","year":"2016","journal-title":"Lancet HIV"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/AOG.0000000000003584","article-title":"Combination antiretroviral therapy and hypertensive disorders of pregnancy","volume":"134","author":"Saums","year":"2019","journal-title":"Obstet. Gynecol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1097\/QAD.0000000000003506","article-title":"Hypertensive disorders of pregnancy and HIV: Analysis of a province-wide cohort during 2018 and 2019","volume":"37","author":"Slogrove","year":"2023","journal-title":"AIDS"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/ijgo.14731","article-title":"Influence of HIV and its treatment on hypertensive disorders of pregnancy in women from a low- to middle-income country","volume":"162","author":"Imogie","year":"2023","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Phoswa, W.N. (2021). The role of HIV infection in the pathophysiology of gestational diabetes mellitus and hypertensive disorders of pregnancy. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.613930"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e2419268","DOI":"10.1001\/jamanetworkopen.2024.19268","article-title":"Nonadjuvanted bivalent respiratory syncytial virus vaccination and perinatal outcomes","volume":"7","author":"Son","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_52","unstructured":"Advisory Committee on Immunization Practices (ACIP) (2024). RSVpreF Vaccine, Preterm Birth, and Small for Gestational Age at Birth Preliminary Results from the Vaccine Safety Datalink (23 October 2024 Presentation), Centers for Disease Control and Prevention (CDC)."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e2419229","DOI":"10.1001\/jamanetworkopen.2024.19229","article-title":"Perinatal outcomes after RSV vaccination during pregnancy\u2014Addressing emerging concerns","volume":"7","author":"Regan","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/QCO.0b013e3283607a58","article-title":"Maternal immunization as a strategy to decrease susceptibility to infection in newborn infants","volume":"26","author":"Lindsey","year":"2013","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Alonso, S., Vidal, M., Ruiz-Olalla, G., Gonz\u00e1lez, R., Manaca, M.N., Jairoce, C., V\u00e1zquez-Santiago, M., Balcells, R., Vala, A., and Rup\u00e9rez, M. (2021). Reduced placental transfer of antibodies against a wide range of microbial and vaccine antigens in HIV-infected women in Mozambique. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.614246"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Taton, M., Willems, F., Widomski, C., Georges, D., Martin, C., Jiang, Y., Renard, K., Konopnicki, D., Cogan, A., and Necsoi, C. (2024). HIV-related immune activation attenuates polyfunctional IgG and memory B-cell responses to Tdap immunization during pregnancy. EBioMedicine, 104.","DOI":"10.1016\/j.ebiom.2024.105179"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Abu-Raya, B., Smolen, K.K., Willems, F., Kollmann, T.R., and Marchant, A. (2016). Transfer of maternal antimicrobial immunity to HIV-exposed uninfected newborns. Front. Immunol., 7.","DOI":"10.3389\/fimmu.2016.00338"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1016\/j.vaccine.2022.06.034","article-title":"Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries","volume":"40","author":"Atwell","year":"2022","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Coler, C., King-Nakaoka, E., Every, E., Chima, S., Vong, A., Del Rosario, B., VanAbel, R., and Adams Waldorf, K.M. (2024). Impact of infections during pregnancy on transplacental antibody transfer. Vaccines, 12.","DOI":"10.3390\/vaccines12101199"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.4161\/hv.29635","article-title":"Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants","volume":"10","author":"Forbes","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jama.2023.5076","article-title":"Antiretroviral Treatment of HIV\/AIDS During Pregnancy","volume":"329","author":"Eke","year":"2023","journal-title":"JAMA J. Am. Med. Assoc."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/12\/1218\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:35:40Z","timestamp":1764740140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/12\/1218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":61,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["vaccines13121218"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13121218","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}